Effects of Low dose abobotulinum toxin A injection in allergic rhinitis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200526014

Enrollment

Registered

2020-05-26

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis Allergic rhinitis

Interventions

Injection of botulinum toxin A to both inferior turbinate of nose&#44

10 units per side (Total = 20 units),Injection of botulinum toxin A to both inferior turbinate of nose&#44

15 units per side (Total = 30 units),Injection of botulinum toxin A to both inferior turbinate of nose&#44

20 units per side (Total = 40 units)

Active Comparator Drug,Active Comparator Drug,Active Comparator Drug

Botulinum toxin A injection 20 units,Botulinum toxin A injection 30 units,Botulinum toxin A injection 40 units

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Diagnose allergic rhinitis by physician with 1.1 positive skin prick test 1.2 perennial allergic rhinitis 1.3 not use antihistamine, intranasal steroid, decongestant drug in previous 1 month before enroll study 2. age 18-60 year olds

Exclusion criteria

Exclusion criteria: 1)pregnancy 2)sinusitis 3)significant anatomical obstruction of nose e.g. deviated nasal septum 4)nasal mass e.g. polyp, tumor 5)history of sinus/nose surgery 6)underlying diseases that contraindicate to botulinum toxin e.g. BPH, galucoma

Design outcomes

Primary

Measure	Time frame
Nasal symptoms week at 1,2,4,8,12 Six point scale	—

Secondary

Measure	Time frame
Ocular symptoms week at 1,2,4,8,12 Six point scale	—

Countries

Thailand

Contacts

Public ContactWorakit pornumnouy

Faculty of medicine, Khon Kaen University

yean202@gmail.com0973207272

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026